VIVUS — Technical Presentation (October 2010)
13 slides from VIVUS's technical presentation, Oct 25, 2010
Slide 1: Cardiometabolic Risk Reduction Associated With Magnitude of Weight Loss With PHEN/TPM CR
Amount of Cardiometabolic Risk Reduction Is Directly Associated With Magnitude of Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate Louis J. Aronne, MD New York-Presbyterian/Weill Cornell University, New York, NY Samuel Klein, MD William H. Danforth Professor of Medicine and Nutri
Slide 2: Disclosures
Dr. Aronne has the following consulting and financial relationships to disclose: Grant/Research Support: Amylin, Arena, Merck, Orexigen, Pfizer, Vivus Consultant: GlaxoSmithKline, Neurosearch, Pfizer Major Stock Shareholder: Cardiometabolic Support Network Dr. Klein has the following consulting and
Slide 3: Obesity, Cardiometabolic Risk, and PHEN/TPM CR
Obesity is an important risk factor for coronary heart disease and the metabolic syndrome1-6 ; weight loss can improve each cardiometabolic risk factor7 Phentermine (PHEN) is a sympathomimetic drug approved in the United States for short-term treatment of obesity 8 Topiramate (TPM) has demonstrated
Slide 4: Mean Percent Weight Loss at Week 56
Mean Percent Weight Loss at Week 56 *P<0.0001 vs placebo -1.2 -7.8* -9.8* -14 -12 -10 -8 -6 -4 -2 0 ITT-LOCF LS Mean Percent Weight Loss 5
Slide 5: Percentage of Subjects Achieving Weight Loss Thresholds
Percentage of Subjects Achieving Weight Loss Thresholds (ITT-LOCF) *P<0.0001 vs placebo The majority of subjects with >10 and >15% weight loss were in the PHEN/TPM CR treated groups 20.8 7.4 2.9 62.1* 37.3* 19.3* 70.0* 47.6* 28.8* 0 10 20 30 40 50 60 70 80 >5% Weight Loss >10% Weight Loss >15% Weigh
Slide 6: Challenging Conventional Wisdom
This analysis proposes to address: Does 5% weight loss lead to meaningful metabolic change/benefit? Does 10% or greater weight loss yield greater effects? Challenging Conventional Wisdom 1. NHLBI 2000. 2. ADA. Diabetes Care 2010. 3. Pi-Sunyer. Postgrad Med 2009. Weight loss of 5-10% has been propose
Slide 7: Categorical Weight Loss Analysis
The whole study population was pooled and then categorized into 3 weight loss categories (regardless of treatment assignment or dose): > 5 to <10% > 10 to <15% >15% Metabolic parameters were then assessed as change from baseline, in absolute values (mmHg, cm, mmol/L), by weight loss category to answ
Slide 8: Absolute Change in Blood Pressure and Waist Circumference by Weight Loss Category
9 Absolute Change in Blood Pressure and Waist Circumference by Weight Loss Category P=0.029 P<0.0001 P=0.0005 P=0.028 P=0.005 Weight Loss Category P<0.0001 P<0.0001 P<0.0001 128.4 129.3 127.7 81.0 80.9 80.0 At baseline: 114.0 112.9 113.5 At baseline: Systolic BP Diastolic BP Waist Circumference - 4.
Slide 9: Absolute Change in Lipid Parameters by Weight Loss Category
10 Absolute Change in Lipid Parameters by Weight Loss Category Weight Loss Category 48.3 49.7 48.8 166.7 165.8 161.2 At baseline: P<0.0001 P<0.0001 P<0.0001 P<0.0001 P<0.0001 P<0.0001 HDL-C Triglycerides 0.03 - 0.20 0.09 - 0.47 0.17 - 0.69 - 0.8 - 0.7 - 0.6 - 0.5 - 0.4 - 0.3 - 0.2 - 0.1 0.0 0.1 0.2
Slide 10: Absolute Change in Glycemic Parameters by Weight Loss Category
11 Absolute Change in Glycemic Parameters by Weight Loss Category P<0.0001 P=0.0348 Weight Loss Category P=0.0002 P=0.0008 P<0.0001 P<0.0001 105.5 106.4 104.3 At baseline: Fasting Glucose HbA1c (%) 5.8 5.9 5.8 - 0.2 - 0.4 - 0.6 - 0.7 - 0.6 - 0.5 - 0.4 - 0.3 - 0.2 - 0.1 0.0 LS Mean Change from Baseli
Slide 11: Most Commonly Reported Treatment-Emergent Adverse Effects
12 Most Commonly Reported Treatment-Emergent Adverse Effects (AEs) Adverse Event (Preferred Term) Placebo (n=993) (%) 7.5/46 (n=498) (%) 15/92 (n=994) (%) Dry mouth 2.4 13.5 20.8 Paresthesia 2.0 13.7 20.5 Constipation 5.9 15.1 17.4 Upper respiratory tract infection 12.9 12.2 13.4 Dysgeusia 1.1 7.4 1
Slide 12: Safety Summary
13 Safety Summary Treatment-emergent serious AEs comparable: 3.8% in placebo vs 3.8% in all PHEN/TPM CR groups Discontinuation rates due to treatment-emergent AEs: 8.9% for placebo 11.6% for 7.5/46 19.2% for 15/92 Reasons for discontinuations occurring at >1% frequency (max. 1.6%): paresthesia, dizz
Slide 13: Conclusions
14 Both doses of PHEN/TPM CR led to significantly greater weight loss vs placebo at 56 weeks, with higher percentages of PHEN/TPM CR subjects achieving >5%, >10%, and >15% weight loss compared to placebo Treatment was generally well tolerated, with dose-related increases in adverse effects. The most